[Irritable bowel syndrome: issues of diagnosis and treatment efficiency].
Loranskaia
I D
ID
D000930:Antidiarrheals / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis* / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D054368:Laxatives / Q000008:administration & dosage / Q000627:therapeutic use; D010276:Parasympatholytics / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D000930:Antidiarrheals; D005765:Gastrointestinal Agents; D054368:Laxatives; D010276:Parasympatholytics; D017366:Serotonin Receptor Agonists